Suppr超能文献

磺酰脲类药物的自由基清除活性:格列齐特作用效果的临床评估

Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.

作者信息

Jennings P E, Belch J J

机构信息

Department of Medicine, York District Hospital, UK.

出版信息

Metabolism. 2000 Feb;49(2 Suppl 1):23-6. doi: 10.1016/s0026-0495(00)80081-5.

Abstract

In long-term clinical studies the beneficial effects of gliclazide on platelets have been related to a reduction in oxidative stress. This property is because of gliclazide's free radical scavenging ability that relates to the unique amino azabicyclo-octare ring, which is grafted on to the sulfonylurea. During a blinded clinical trial, the possible effects of gliclazide were assessed in 30 non-insulin-dependent diabetic patients. All patients had been treated for diabetes for more than 2 years (mean 8 years) and had been established on glibenclamide for over 2 years with or without adjunctive metformin therapy. Patients were studied for 6 months and randomized to continue either their present dose of glibenclamide or to be converted to an equipotent dose of gliclazide. Measurements were taken of hemostatic variables, the oxidative status of the plasma, and the redox status, both extracellularly as plasma albumin-thiols (PSH) and lipid peroxides, and intracellularly as red blood cell superoxide dismutase activity (SOD). At 3 months, diabetic control was unaltered, but there were significant improvements in the oxidative status of the gliclazide-treated patients. Lipid peroxides decreased (8.3 +/- 1.1 to 7.0 +/- .06 micromol/L, P < .01) and red blood cell SOD increased (135 +/- 21 to 152 +/- 36 microg/mL, P < .05). PSH levels were unaltered at 458 +/- 38 micromol/L, whereas they had decreased significantly in the glibenclamide patients (414 +/- 34 micromol/L, P < .05), resulting in a significant difference between the 2 treatment groups (P < .004). Platelet reactivity to collagen also improved in the gliclazide-treated patients, decreasing from 65.1% +/- 14% to 50.8% +/- 24% (P < .01). The reactivity of the platelets remained unaltered in the glibenclamide patients. At 6 months, the significant differences between the 2 treatment groups remained. Hence, gliclazide was shown in a clinical study to have free radical scavenging activity independent of glycemic control.

摘要

在长期临床研究中,格列齐特对血小板的有益作用与氧化应激的降低有关。这一特性归因于格列齐特的自由基清除能力,该能力与接枝于磺酰脲的独特氨基氮杂双环辛烷环有关。在一项双盲临床试验中,对30例非胰岛素依赖型糖尿病患者评估了格列齐特可能的作用。所有患者糖尿病病程均超过2年(平均8年),且使用格列本脲治疗超过2年,接受或未接受二甲双胍辅助治疗。对患者进行了6个月的研究,并随机分为继续使用当前剂量的格列本脲或转换为等效剂量的格列齐特。对止血变量、血浆氧化状态以及氧化还原状态进行了测量,细胞外测量血浆白蛋白硫醇(PSH)和脂质过氧化物,细胞内测量红细胞超氧化物歧化酶活性(SOD)。3个月时,糖尿病控制情况未改变,但格列齐特治疗组患者的氧化状态有显著改善。脂质过氧化物减少(从8.3±1.1降至7.0±0.06μmol/L,P<0.01),红细胞SOD增加(从135±21升至152±36μg/mL,P<0.05)。PSH水平在458±38μmol/L时未改变,而格列本脲组患者的PSH水平显著降低(414±34μmol/L,P<0.05),导致两个治疗组之间存在显著差异(P<0.004)。格列齐特治疗组患者血小板对胶原的反应性也有所改善,从65.1%±14%降至50.8%±24%(P<0.01)。格列本脲组患者血小板的反应性保持不变。6个月时,两个治疗组之间的显著差异仍然存在。因此,一项临床研究表明格列齐特具有独立于血糖控制的自由基清除活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验